Paying user area
Try for free
AbbVie Inc. pages available for free this week:
- Common-Size Balance Sheet: Assets
- Analysis of Profitability Ratios
- Analysis of Short-term (Operating) Activity Ratios
- Enterprise Value (EV)
- Price to FCFE (P/FCFE)
- Selected Financial Data since 2012
- Debt to Equity since 2012
- Price to Operating Profit (P/OP) since 2012
- Analysis of Debt
- Aggregate Accruals
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to AbbVie Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Calculation
P/BV | = | Share price1, 2, 3 | ÷ | Book value per share1 (BVPS) | BVPS1 | = | Stockholders’ equity (deficit)1 (in millions) |
÷ | No. shares of common stock outstanding2 | ||
---|---|---|---|---|---|---|---|---|---|---|---|
Feb 14, 2025 | = | ÷ | = | ÷ | |||||||
Feb 20, 2024 | = | ÷ | = | ÷ | |||||||
Feb 17, 2023 | = | ÷ | = | ÷ | |||||||
Feb 18, 2022 | = | ÷ | = | ÷ | |||||||
Feb 19, 2021 | = | ÷ | = | ÷ | |||||||
Feb 21, 2020 | = | ÷ | = | ÷ | |||||||
Feb 27, 2019 | = | ÷ | = | ÷ | |||||||
Feb 16, 2018 | = | ÷ | = | ÷ | |||||||
Feb 17, 2017 | = | ÷ | = | ÷ | |||||||
Feb 19, 2016 | = | ÷ | = | ÷ | |||||||
Feb 20, 2015 | = | ÷ | = | ÷ | |||||||
Feb 21, 2014 | = | ÷ | = | ÷ | |||||||
Mar 15, 2013 | = | ÷ | = | ÷ |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31).
1 US$
2 Data adjusted for splits and stock dividends.
3 Closing price as at the filing date of AbbVie Inc. Annual Report.
The share price of the company demonstrates an overall upward trajectory over the analyzed period, increasing from $38.50 in March 2013 to $192.87 by February 2025. Notable fluctuations occur throughout the years, with marked increases between February 2017 and February 2018, where the share price nearly doubled from $61.77 to $118.60. Subsequently, the price experiences some volatility but generally trends upwards, reaching levels above $150 from 2022 onward, indicating strong market valuation growth.
The book value per share (BVPS) exhibits considerable volatility compared to the share price. Initially, BVPS started modestly at $2.13 in 2013 and increased slightly until early 2018, reaching $3.21. However, significant negative values are recorded in 2019 and 2020, at approximately -$5.73 and -$5.52 respectively, indicating possible accounting write-downs or substantial losses that impacted equity negatively. Following this downturn, BVPS rebounds sharply, peaking at $9.75 in 2023 before declining again to $1.88 by 2025. This pattern suggests instability in the book value, potentially reflecting changes in equity structure, asset valuation adjustments, or extraordinary items affecting the balance sheet.
The price-to-book value ratio (P/BV) shows an inconsistent pattern closely influenced by the volatility of BVPS. Early in the period, the ratio remains relatively high, around 18.0 in 2013 and 2014, then spikes dramatically to over 56.0 in 2015, reflecting the low BVPS at that time. During 2016 and 2017, the ratio stabilizes somewhat in the low 20s but climbs again to 36.95 in 2018. The data is missing for 2019 and 2020 but resumes in 2021 with values ranging from 14.18 to 16.53, indicating a recalibration in market valuation relative to book value. However, significant increases in P/BV occur in the most recent years, reaching 102.4 by 2025, suggesting that the market price is very high compared to the book value. This may reflect strong investor confidence or expectations of future growth despite low or declining book value.
Overall, the share price trend indicates positive market sentiment and possibly strong operational performance or growth prospects. In contrast, the BVPS volatility and occasional negative values point to underlying challenges or accounting impacts affecting the company's net asset base. The P/BV ratio underscores the disparity between market valuation and book value, emphasizing investor willingness to value the company at a premium relative to its stated equity base, especially in recent periods.
Comparison to Competitors
AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Feb 14, 2025 | ||||||||||||
Feb 20, 2024 | ||||||||||||
Feb 17, 2023 | ||||||||||||
Feb 18, 2022 | ||||||||||||
Feb 19, 2021 | ||||||||||||
Feb 21, 2020 | ||||||||||||
Feb 27, 2019 | ||||||||||||
Feb 16, 2018 | ||||||||||||
Feb 17, 2017 | ||||||||||||
Feb 19, 2016 | ||||||||||||
Feb 20, 2015 | ||||||||||||
Feb 21, 2014 | ||||||||||||
Mar 15, 2013 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
AbbVie Inc., P/BV, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
AbbVie Inc. | Pharmaceuticals, Biotechnology & Life Sciences | |
---|---|---|
Feb 14, 2025 | ||
Feb 20, 2024 | ||
Feb 17, 2023 | ||
Feb 18, 2022 | ||
Feb 19, 2021 | ||
Feb 21, 2020 | ||
Feb 27, 2019 | ||
Feb 16, 2018 | ||
Feb 17, 2017 | ||
Feb 19, 2016 | ||
Feb 20, 2015 | ||
Feb 21, 2014 | ||
Mar 15, 2013 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31).
Comparison to Industry (Health Care)
AbbVie Inc. | Health Care | |
---|---|---|
Feb 14, 2025 | ||
Feb 20, 2024 | ||
Feb 17, 2023 | ||
Feb 18, 2022 | ||
Feb 19, 2021 | ||
Feb 21, 2020 | ||
Feb 27, 2019 | ||
Feb 16, 2018 | ||
Feb 17, 2017 | ||
Feb 19, 2016 | ||
Feb 20, 2015 | ||
Feb 21, 2014 | ||
Mar 15, 2013 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31).